| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial †
|
Mounier, N.
|
|
|
25 |
8 |
p. 1622-1628
|
artikel
|
| 2 |
Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study
|
Buzzoni, R.
|
|
|
25 |
8 |
p. 1597-1603
|
artikel
|
| 3 |
Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies
|
Turati, F.
|
|
|
25 |
8 |
p. 1526-1535
|
artikel
|
| 4 |
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
|
Choueiri, T.K.
|
|
|
25 |
8 |
p. 1603-1608
|
artikel
|
| 5 |
Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
|
Ali, H.R.
|
|
|
25 |
8 |
p. 1536-1543
|
artikel
|
| 6 |
Carboplatin's fourth decade: still searching for its sweet spot
|
Quinn, D.I.
|
|
|
25 |
8 |
p. 1457-1458
|
artikel
|
| 7 |
Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research
|
Grover, P.K.
|
|
|
25 |
8 |
p. 1506-1516
|
artikel
|
| 8 |
Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor
|
De Cecco, L.
|
|
|
25 |
8 |
p. 1628-1635
|
artikel
|
| 9 |
Controversial issues in early-stage breast cancer: a global collaborative survey, supported by the European Society for Medical Oncology (ESMO)
|
Zardavas, D.
|
|
|
25 |
8 |
p. 1558-1562
|
artikel
|
| 10 |
Controversies and role of HPV16 in recurrent/metastatic squamous cell cancers of the head and neck
|
Misiukiewicz, K.
|
|
|
25 |
8 |
p. 1667-1668
|
artikel
|
| 11 |
Corrections to “Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer”
|
|
|
|
25 |
8 |
p. 1672
|
artikel
|
| 12 |
Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force
|
Aapro, M.
|
|
|
25 |
8 |
p. 1492-1499
|
artikel
|
| 13 |
Early-stage lung cancer—what do the experts recommend?
|
Leighl, N.B.
|
|
|
25 |
8 |
p. 1451-1453
|
artikel
|
| 14 |
Editorial Board
|
|
|
|
25 |
8 |
p. ii-iii
|
artikel
|
| 15 |
ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas
|
Wilhelm, M.
|
|
|
25 |
8 |
p. 1500-1505
|
artikel
|
| 16 |
European cancer mortality predictions for the year 2014
|
Malvezzi, M.
|
|
|
25 |
8 |
p. 1650-1656
|
artikel
|
| 17 |
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression †
|
Nitz, U.
|
|
|
25 |
8 |
p. 1551-1557
|
artikel
|
| 18 |
‘Fracture incidence after 3 years of aromatase inhibitor therapy’
|
Laurent, M.R.
|
|
|
25 |
8 |
p. 1665-1666
|
artikel
|
| 19 |
Immigrants' perceptions of the quality of their cancer care: an Australian comparative study, identifying potentially modifiable factors
|
Goldstein, D.
|
|
|
25 |
8 |
p. 1643-1649
|
artikel
|
| 20 |
Immunoscoring breast cancer: TILs remember what they target
|
Curigliano, G.
|
|
|
25 |
8 |
p. 1455-1456
|
artikel
|
| 21 |
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
|
Nabholtz, J.M.
|
|
|
25 |
8 |
p. 1570-1577
|
artikel
|
| 22 |
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
|
Vansteenkiste, J.
|
|
|
25 |
8 |
p. 1462-1474
|
artikel
|
| 23 |
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
|
Besse, B.
|
|
|
25 |
8 |
p. 1475-1484
|
artikel
|
| 24 |
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
|
Balmaña, J.
|
|
|
25 |
8 |
p. 1656-1663
|
artikel
|
| 25 |
Plasma methionine, choline, betaine, and dimethylglycine in relation to colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)
|
Nitter, M.
|
|
|
25 |
8 |
p. 1609-1615
|
artikel
|
| 26 |
‘Pre-cachexia’: a non-existing phenomenon in cancer?
|
Blauwhoff-Buskermolen, S.
|
|
|
25 |
8 |
p. 1668-1669
|
artikel
|
| 27 |
Quality assurance in the treatment of colorectal cancer: the EURECCA initiative
|
Breugom, A.J.
|
|
|
25 |
8 |
p. 1485-1492
|
artikel
|
| 28 |
Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer
|
Mok, T.S.
|
|
|
25 |
8 |
p. 1578-1584
|
artikel
|
| 29 |
RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma
|
Diwakar, D.
|
|
|
25 |
8 |
p. 1670-1671
|
artikel
|
| 30 |
Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort
|
Cathomas, R.
|
|
|
25 |
8 |
p. 1591-1597
|
artikel
|
| 31 |
Reply to the letter to the editor ‘Fracture incidence after 3 years of aromatase inhibitor therapy’ by Laurent et al.
|
Bouvard, B.
|
|
|
25 |
8 |
p. 1666-1667
|
artikel
|
| 32 |
Risks of the new EU Data protection regulation: an ESMO position paper endorsed by the European oncology community
|
Casali, P.G.
|
|
|
25 |
8 |
p. 1458-1461
|
artikel
|
| 33 |
Should we use the angiotensin-converting enzyme inhibitors for the treatment of anti-VEGF-induced hypertension?
|
Emile, G.
|
|
|
25 |
8 |
p. 1669-1670
|
artikel
|
| 34 |
Smoking and survival of colorectal cancer patients: systematic review and meta-analysis
|
Walter, V.
|
|
|
25 |
8 |
p. 1517-1525
|
artikel
|
| 35 |
SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib
|
Zhang, L.
|
|
|
25 |
8 |
p. 1584-1590
|
artikel
|
| 36 |
Table of Contents
|
|
|
|
25 |
8 |
p. iv-vi
|
artikel
|
| 37 |
The dilemmas of breast cancer treatment and increased fracture risk
|
Malik, L.
|
|
|
25 |
8 |
p. 1664
|
artikel
|
| 38 |
‘The dilemmas of breast cancer treatment and increased fracture risk’ by Malik
|
Bouvard, B.
|
|
|
25 |
8 |
p. 1664-1665
|
artikel
|
| 39 |
The immunogenicity of breast cancer—molecular subtypes matter
|
Denkert, C.
|
|
|
25 |
8 |
p. 1453-1455
|
artikel
|
| 40 |
Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial
|
Kramar, A.
|
|
|
25 |
8 |
p. 1563-1570
|
artikel
|
| 41 |
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|
Loi, S.
|
|
|
25 |
8 |
p. 1544-1550
|
artikel
|
| 42 |
Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial †
|
Glynne-Jones, R.
|
|
|
25 |
8 |
p. 1616-1622
|
artikel
|
| 43 |
Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA)
|
Blum, D.
|
|
|
25 |
8 |
p. 1635-1642
|
artikel
|
Tijdschrift beschrijving